



### Ergoresearch: At the Heart of Motion

#### Custom Orthotics



#### Bimodal Sensor System



#### OdrA Orthotic Device: A Revolutionary Knee Osteoarthritis Treatment



## A SECTOR IN FULL GROWTH

### CORPORATE PROFILE

Since 2005, Ergoresearch has developed the most important network of orthotics clinics in Quebec, with over 60 corporate centres and satellites under the Clinique du pied Équilibre and Orthoconcept banners. Ergoresearch proposes innovative orthopedic solutions and products offering peak impact on pain and function. These products are economically efficient and often reimbursed by private or public insurance plans. The firm's products are biomechanical, non-invasive and non-toxic. Patient benefits are well supported by a substantial body of clinical proof, and convincing scientific data.

### A COMPANY IN FULL GROWTH

The leading manufacturer of "intelligent" custom-fit foot orthotics and specialty orthotics, Ergoresearch is at the avant-garde in the field of specialized medical equipment and software for the orthopedic market.

The firm was the first to develop and commercialize podo-barometric sensor pads on a large scale, and to use two distinct software programs to ensure the quality and performance of its orthotics. This state of the art technology has introduced automated production of custom-fit orthotics, crafted by numerically controlled machine tools and computer-aided manufacturing and design software (CAM/CAD).

Ergoresearch is listed on the Toronto Stock Exchange (TSX-V: ERG) and is committed to an ambitious five-year growth strategy. Over 50% of shares are held by members of Ergoresearch directors, joined by a number of healthcare professionals.

### WHY INVEST IN ERGORESEARCH?

- It is a full-growth, profitable company in a continually growing market;
- Its field is in full effervescence owing to:
  - Aging populations and their associated joint problems;
  - High incidences of diabetes and obesity.
- Products offer interesting added values and superior results in the area of pain reduction;
- Strong profit margins draw on the merits of its product line and the firm's commitment to the vertical integration of its assorted activities;
- It offers non-invasive orthopedic devices that lead to diminished reliance on medication.
- Its products are sold by prescription and reimbursed by private or public insurance companies.

### RECENT ACHIEVEMENTS

- September 2012: OdrA Launch – A new generation of orthotics that revolutionizes the treatment of knee osteoarthritis;
- July 2012: President and CEO of Ergoresearch, Sylvain Boucher, is selected as a Quebec finalist for the 2012 Ernst & Young Entrepreneur Of The Year Awards;
- June 2012 – June 2011: For two years in a row, the company has appeared on the prestigious roster of *PROFIT 200 Canada's Fastest-Growing Companies*, as one of the country's most successful 5-year performers;
- October 2011: Ergoresearch is listed on *Deloitte's Technology Fast 500*;
- June 2011: For the first time in its history, Ergoresearch ranks **10<sup>th</sup> at Quebec's annual Leaders de la croissance** published by L'Actualité Magazine – **a strong first place in the medical field** in the province;
- May 2011: **Launch of the first Living Lab for knee osteoarthritis in Canada**, a centre for transdisciplinary excellence located at Complexe ERGO, in Laval.





**ERGORESEARCH**



**Expert-Fit**

**Trading:**

**ERG**  
Toronto Stock Exchange (TSX-V)

**Fiscal Year-End**  
**June 30**

**Recent Price** (October 23 2012)  
**\$0.44**

**Common Shares Issued**  
**59 631 275**

**General Information**

**Ergoresearch Ltd**  
2101, boul. Le Carrefour, Suite 200  
Laval (Quebec) H7S 2J7

**Financial Reports**  
[www.sedar.com](http://www.sedar.com)

**Transfer Agent**  
**Equity Transfer & Trust Company**  
200, University Avenue, Suite 400  
Toronto (Ontario) M5H 4H1

**CUSIP NUMBER**  
**29482C**

**Auditors**  
**RSM Richter Chamberland**  
**S.E.N.C.R.L./LLP**  
Place Alexis Nihon, Suite 1820  
Montreal (Quebec) H3Z 3C2

**Investor Relations**  
Please address your requests  
for information to  
[info@ergoresearch.com](mailto:info@ergoresearch.com)

**Website:**  
[www.ergoresearch.com](http://www.ergoresearch.com)

## ROBOTICS PRODUCTION PLANT


**Expert-fit®** proposes to re-create the architecture of the foot. The unique custom fit design of its orthotics is based on each patient's own anthropometric measurements and pressure distribution data. The personal analysis is then transmitted to the firm's computational servers to create optimal orthotic designs using computer-aided design (CAD) software. The manufacturing process that relies on computer-aided manufacturing software (CAM) and numerically controlled machine tools (NCMT) offers the ability to produce made-to-measure orthotics while ensuring reproducibility and precision. Owing to the company's software programs and mobile devices, patients are assessed and their custom orthotics ordered without ever leaving their physician's office.

## ODRA: NEW WORLDWIDE PATENT


In September 2012, Ergoresearch was confirmed as a leader once again when it launched a new generation of orthotics, exclusive on Canadian markets – the OdrA orthotic device, a revolutionary advance in the treatment of knee OA. World-patented and developed by Proteor – Ergoresearch's partner and France's leading orthopedic provider – the OdrA or distraction and rotation knee OA orthotic device improves knee mobility and reduces inner joint pressure causing pain that affects close to 300,000 Quebecers / 1.2 million Canadians.

## FINANCIAL PERFORMANCE

**Evolution of Sales**



**EBITDA**



## OVERVIEW

- Innovative products and solutions offering superior results in pain management and motor function;
- Biomechanical-type products (class 1), non-invasive and non-toxic;
- Well documented clinical proof and convincing scientific data;
- Patented mobile technologies exclusive to Ergoresearch;
- Growth strategy rooted in innovation paired with ambitious acquisitions program;
- Efficient economic engine with recurring earnings;
- Exclusive OdrA distribution rights in Canada, a revolutionary new orthotic device for treating knee OA;
- Canada's knee OA market is evaluated at \$27.5b;
- Profit generation since 2005.

**Caution Regarding Forward-Looking Statements** – Certain statements in this document, including those that express predictions or estimations regarding the Company's future-looking earnings, represent future-looking statements compliant with applicable securities legislation. While forward-looking statements are based on predictions and hypotheses, the Company considers these factors and assumptions to be reasonable based on information currently available. However, they are inherently subject to uncertainty and represent not insignificant risk on commercial, economic and competitive levels. We caution investors against unduly relying on forward-looking statements. This corporate fact sheet should be read in combination with the Company's financial report and its latest annual report, available at [www.sedar.com](http://www.sedar.com).